Bayesian cancer clinical trial designs with subgroup-specific decisions

Area of Science:

• Biostatistics
• Clinical Trial Design
• Medical Research

Background:

• Adaptive clinical trial designs offer flexibility in decision-making.
• Subgroup analysis is crucial for personalized medicine.
• Quantifying risk-benefit trade-offs is essential for ethical trial conduct.

Purpose of the Study:

• To present Bayesian adaptive clinical trial designs for subgroup-specific decisions.
• To illustrate these designs in oncology trials (esophageal cancer, hematologic malignancies).
• To evaluate the performance of these designs against simpler comparators.

Main Methods:

• Utilized Bayesian hierarchical models for borrowing strength across subgroups.
• Incorporated elicited utilities to quantify patient outcome risk-benefit trade-offs.
• Employed computer simulations to assess design properties and robustness.

Main Results:

• Bayesian adaptive designs accounting for treatment-subgroup interactions showed desirable properties.
• These advanced designs significantly outperformed simpler designs that ignored interactions.
• The proposed designs demonstrated robustness to model deviations.

Conclusions:

• Bayesian adaptive subgroup-specific designs are highly effective for clinical trials.
• Prospective consideration of treatment-subgroup interactions enhances trial efficiency and decision-making.
• These methods provide a superior framework for evaluating interventions in diverse patient populations.